Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT02278445

Evaluation of Pulmonary Doppler Signals in Patients With Systemic Sclerosis(SSc)

Evaluation of Lung Doppler Signals (LDS) in Detecting Pulmonary Arterial Hypertension in Patients With Systemic Sclerosis (SSc)

Status
Withdrawn
Phase
N/A
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Echosense Ltd. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package- the Transthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa, Israel). Systemic sclerosis patients often develop pulmonary vascular disease leading to pulmonary hypertension. The TPD system may provide important insight into pulmonary blood vessels characteristics by the LDS (Lung Doppler Signals) signals that are related to pulmonary hypertension. The TPD performance in detecting PAH in SSc patients will be assessed in the study.

Conditions

Interventions

TypeNameDescription
RADIATIONDoppler ultrasoundRecording Doppler ultrasound noninvasively from the right chest wall
DEVICETransthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa, Israel)

Timeline

Start date
2014-11-01
Primary completion
2015-11-01
Completion
2015-12-01
First posted
2014-10-30
Last updated
2015-12-02

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT02278445. Inclusion in this directory is not an endorsement.